The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kade A.Kh.

Kuban State Medical University, Krasnodar, Russia

Kravchenko S.V.

Kuban State Medical University, Krasnodar, Russia

Trofimenko A.I.

Scientific Research Institute — Ochapovsky Regional Clinical Hospital #1, Krasnodar, Russia

Chaplygina K.Yu.

Kuban State Medical University, Krasnodar, Russia

Ananeva E.I.

Kuban State Medical University, Krasnodar, Russia

Poliakov P.P.

Kuban State Medical University, Krasnodar, Russia

Lipatova A.S.

Kuban State Medical University, Krasnodar, Russia

The efficacy of tes-therapy for treatment of anxiety-like behavior and motor disorders in rats with an experimental model of parkinsonism

Authors:

Kade A.Kh., Kravchenko S.V., Trofimenko A.I., Chaplygina K.Yu., Ananeva E.I., Poliakov P.P., Lipatova A.S.

More about the authors

Read: 1102 times


To cite this article:

Kade AKh, Kravchenko SV, Trofimenko AI, Chaplygina KYu, Ananeva EI, Poliakov PP, Lipatova AS. The efficacy of tes-therapy for treatment of anxiety-like behavior and motor disorders in rats with an experimental model of parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):91‑96. (In Russ.)
https://doi.org/10.17116/jnevro201911909191

Recommended articles:
Sporadic form of Guam disease (ALS—parkinsonism—dementia complex). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):135-141
Oxidative stress and dyna­mics of its patterns following therapeutic physical factors in complex therapy of vaso­motor rhinitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):12-21

References:

  1. Schrag A, Taddei RN. Depression and Anxiety in Parkinson’s Disease. In International review of neurobiology. Academic Press. 2017;133:623-655. https://doi.org/10.1016/bs.irn.2017.05.024
  2. Campos FL, Carvalho MM, Cristovão AC, Je G, Baltazar G, Salgado AJ, Kim Y-S, Sousa N. Rodent models of Parkinson’s disease: beyond the motor symptomatology. Frontiers in Behavioral Neuroscience. 2013;7:175. https://doi.org/10.3389/fnbeh.2013.00175
  3. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson’s disease. Journal of Neurochemistry. 2016;139:216-231. https://doi.org/10.1111/jnc.13731
  4. Kornyuhina EYu, Chernikova LA, Ivanova-Smolenskaya IA, Karabanov AV, Fedin PA. Vozdejstvie transkranial’noj ehlektrostimulyacii na ehmocional’no-volevye rasstrojstva i kognitivnye narusheniya pri bolezni Parkinsona. Transkranial’naya ehlektrostimulyaciya. Eksperimental’no-klinicheskie issledovaniya. Sbornik statej. 2009;3:21-28 (In Russ.)
  5. Bonito-Oliva A, Masini D, Fisone G. A mouse model of non-motor symptoms in Parkinson’s disease: focus on pharmacological interventions targeting affective dysfunctions. Frontiers in Behavioral Neuroscience. 2014;8:290. https://doi.org/10.3389/fnbeh.2014.00290
  6. Shin M-S, Kim T-W, Lee J-M, Sung Y-H, Lim B-V. Treadmill exercise alleviates depressive symptoms in rotenone-induced Parkinson disease rats. Journal of Exercise Rehabilitation. 2017;13(2):124-129. https://doi.org/10.12965/jer.1734966.483
  7. Jagmag SA, Tripathi N, Shukla SD, Maiti S, Khurana S. Evaluation of models of Parkinson’s disease. Frontiers in Neuroscience. 2016;9:503. https://doi.org/10.3389/fnins.2015.00503
  8. Malinovskaya NA, Gasymly ED, Baglaeva OV, Bazarova AS, Pishchikov OV. Eksperimental’nye rotenonovye modeli bolezni Parkinsona na krysah. Nauchnye Trudy SWorld. 2012;43(4):57-61. (In Russ.)
  9. Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Wang T. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models. Critical Reviews in Toxicology. 2012;42(7):613-632. https://doi.org/10.3109/10408444.2012.680431
  10. Abdelkader NF, Arafa NM, Attia AS, Ain-Shoka AA, Abdallah DM. Pyrrolidine dithiocarbamate ameliorates rotenone-induced Parkinson’s disease in rats. Bulletin of Faculty of Pharmacy, Cairo University. 2017;55(1):107-113. https://doi.org/10.1016/j.bfopcu.2016.11.003
  11. Ren Y, Feng J. Rotenone selectively kills serotonergic neurons through a microtubule‐dependent mechanism. Journal of Neurochemistry. 2007;103(1);303-311. https://doi.org/10.1111/j.1471-4159.2007.04741.x
  12. Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex I inhibitor rotenone in the context of pharmacological and safety evaluation. Scientific Reports. 2017;7(1):45465. https://doi.org/10.1038/srep45465
  13. Chernivec E, Cooper J, Naylor K. Exploring the Effect of Rotenone—A Known Inducer of Parkinson’s Disease — On Mitochondrial Dynamics in Dictyostelium discoideum. Cells. 2018;7(11):201. https://doi.org/10.3390/cells7110201
  14. Streck EL, Gonçalves CL, Furlanetto CB, Scaini G, Dal-Pizzol F, Quevedo J. Mitochondria and the central nervous system: searching for a pathophysiological basis of psychiatric disorders. Revista Brasileira de Psiquiatria. 2014;36(2):156-167. https://doi.org/10.1590/1516-4446-2013-1224
  15. Fregni F, Nitsche MA, Loo CK, Brunoni AR, Marangolo P, Leite J, Simis M. Regulatory considerations for the clinical and research use of transcranial direct current stimulation (tDCS): review and recommendations from an expert panel. Clinical Research and Regulatory Affairs. 2015;32(1):22-35.
  16. Woods AJ, Antal A, Bikson M, Boggio PS, Brunoni AR, Celnik P, Knotkova H. A technical guide to tDCS, and related non-invasive brain stimulation tools. Clinical Neurophysiology. 2016;127(2):1031-1048. https://doi.org/10.1016/j.clinph.2015.11.012
  17. Winkler C, Reis J, Hoffmann N, Gellner AK, Münkel C, Curado MR, Fritsch B. Anodal transcranial direct current stimulation enhances survival and integration of dopaminergic cell transplants in a rat parkinson model. Eneuro. 2017;4(5):ENEURO.0063-17.2017. https://doi.org/10.1523/eneuro.0063-17.2017
  18. Ferrucci R, Cortese F, Bianchi M, Pittera D, Turrone R, Bocci T, Di Fonzo A. Cerebellar and motor cortical transcranial stimulation decrease levodopa-induced dyskinesias in Parkinson’s disease. The Cerebellum. 2016;15(1):43-47. https://doi.org/10.1007/s12311-015-0737-x
  19. Zanin SA, Kade AH, Kadomcev DV, Pasechnikova EA, Golubev VG, Plotnikova VV, Sharov MA, Azarkin EV, Kocharyan VEh. TES-terapiya. Sovremennoe sostoyanie problemy. Sovremennye Problemy nauki i Obrazovaniya. 2017;1:58-58. (In Russ.)
  20. Zaghi S, Acar M, Hultgren B, Boggio PS, Fregni F. Noninvasive brain stimulation with low-intensity electrical currents: putative mechanisms of action for direct and alternating current stimulation. The Neuroscientist. 2010;16(3):285-307. https://doi.org/10.1177/1073858409336227
  21. Guleyupoglu B, Schestatsky P, Edwards D, Fregni F, Bikson M. Classification of methods in transcranial electrical stimulation (tES) and evolving strategy from historical approaches to contemporary innovations. Journal of Neuroscience Methods. 2013;219(2):297-311. https://doi.org/10.1016/j.jneumeth.2013.07.016
  22. Lebedev VP. Transcranial electrostimulation: A new approach (experimental and clinical testing and equipment). Biomedical Engineering. 1997;31(2);66-73. https://doi.org/10.1007/bf02365935
  23. Kade AH, Polyakov PP, Lipatova AS, Sotnichenko AS, Kuevda EV, Gubareva EA. Harakter ehkspressii c-fos nejronami medial’noj prefrontal’noj kory v usloviyah kombinirovannogo stressa i vliyaniya TES-terapii. Sovremennye Problemy Nauki i Obrazovaniya. 2017;5:86-86. (In Russ.) https://doi.org/10.17513/spno.26877
  24. Trofimenko AI, Kade AH, Nekhaj FA, Lebedev VP, Levichkin VD, Zanin SA. Dinamika urovnya β-ehndorfina pri modelirovanii ishemicheskogo insul’ta u krys. Kubanskij Nauchnyj Medicinskij Vestnik. 2014;3:115-118. (In Russ.)
  25. Lipatova AS, Polyakov PP, Kade AH, Trofimenko AI, Kravchenko SV. Vliyanie transkranial’noj elektrostimulyacii na vynoslivost’ krys s raznoj ustojchivost’yu k stressu. Biomedicina. 2018;1:84-91. (In Russ.)
  26. Levichkin VD, Trofimenko AI, Kade AH, Pavlyuchenko II, Zanin SA. Korrekciya pokazatelej prooksidantno-antioksidantnoj sistemy pri ishemicheskom insul’te TES-terapiej. Sovremennye Problemy Nauki i Obrazovaniya. 2014;(4):342-342. (In Russ.)
  27. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Experimental Neurology. 2003;179(1):9-16. https://doi.org/10.1006/exnr.2002.8072
  28. Lipatova AS, Polyakov PP, Kade AH, Zanin SA, Trofimenko AI, Malysheva TV. Modifikaciya metodiki TES-terapii dlya ee primeneniya u melkih laboratornyh gryzunov. Sovremennye Problemy Nauki i Obrazovaniya. 2015;5:347-347. (In Russ.)
  29. Voronina TA, Val’dman EA, Nerobkova LN. Eksperimental’noe izuchenie preparatov s protivoparkinsonicheskoj aktivnost’yu. Vedomosti Nauchnogo Centra Ehkspertizy i Gosudarstvennogo Kontrolya LS. 1999;1. Accessed September 27, 2018. (In Russ.). http://www.drugreg.ru/Doc/Vedomosti/0999-1/Vedomosti0999-1_4-3.htm
  30. Voronina TA, Avakyan GN, Popova OA, Katunina EV, Nerobkova LN, Kapica IG. Osobennosti protivoparkinsonicheskogo dejstviya meksidola v ehksperimente pri modelirovanii parkinsonicheskogo sindroma i v klinike u pacientov s bolezn’yu Parkinsona. Nejrohirurgiya i Nevrologiya Kazahstana. 2008. Accessed September 27, 2018. (In Russ.). http://medi.ru/doc/a070102.htm
  31. Voronkov DN, Dikalova YuV, Hudoerkov RM, Yamshchikova NG. Izmeneniya v nigrostriatnyh obrazovaniyah mozga pri modelirovanii parkinsonizma, inducirovannogo rotenonom (kolichestvennoe immunomorfologicheskoe issledovanie). Annaly Klinicheskoj i Eksperimental’noj Nevrologii. 2013;7(2):34-38. (In Russ.)
  32. Yahno NN, Shtul’man DR, Mel’nichuk PV. Bolezni nervnoj sistemy. M.: Medicina; 2001.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.